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Abstract Aim of the study has been to understand the relationship between TH17 and Treg cell
subsets in patients affected with systemic sclerosis (SSc). Phenotypes and functions of Th17 and
Treg cell subsets were analyzed in a series of 36 SSc patients. Th17 cell concentration in the
peripheral blood was found to be increased in SSc patients with respect to healthy controls
independently from type or stage of disease. After PBMC stimulation with a polyclonal stimulus or
Candida albicans antigens the frequency of Th17 T cell clones was significantly higher in SSc
patients with respect to controls suggesting the skewing of immune response in SSc patients
toward Th17 cell generation/expansion. Concerning the Treg compartment, both CD4+CD25+
and CD8+CD28− Treg subsets showed quantitative and qualitative alteration in the peripheral
blood of SSc patients. Collectively, these data highlight the existence of an imbalanced ratio
between Th17 and Treg cell subsets in SSc patients.
© 2011 Elsevier Inc. All rights reserved.nt of Internal Medicine (DIMI),
XV n. 6, 16132 Genova, Italy.
. Filaci).
1 Elsevier Inc. All rights reserv1. Introduction
Systemic sclerosis (SSc) is a systemic connective tissue disease
characterized by chronic inflammation leading to tissueedfibrosis. Although SSc pathogenesis is still unclear, immune
mediated phenomena are admitted to have a role based on the
presence of circulating autoantibodies and of activated T cells
infiltrating diseased tissues [1]. Among the immune derived
factors sustaining the inflammatory process and its evolution
in fibrosis in SSc, TGFβ, interleukin (IL) 6, and IL1might have a
central role due to their elevated concentrations in tissues/
sera and their capacity to induce fibroblast activation,
proliferation and collagen production [2–5]. Recently, the
same cytokines have been found to be involved in the.
250 D. Fenoglio et al.differentiation/expansion of Th17 cells, a pro-inflammatory T
cell subset secreting IL17 [6–8]. This finding could relate the
inflammatory phenomena and the immune response peculiar
for SSc to the generation of Th17 cells and IL17 secretion.
Indeed, studies assessing IL17 serum levels in SSc patients have
demonstrated the presence of increased IL17 concentrations
in the sera of SSc patients with respect to healthy subjects
[9,10]; moreover, increased frequencies of Th17 cells in both
CD45Ro+ and CD45Ra+CD4+ T cell subsets of SSc patients have
been reported [11].
Interestingly, TGFβ is also involved in the generation of
peripheral regulatory T lymphocytes (Treg) [12]. Treg are
considered of great relevance in inducing peripheral
tolerance of potentially pathogenic autoreactive T cells
[13]. Indeed, Treg alterations have been identified in
several autoimmune diseases including anti-nuclear anti-
bodies (ANA) positive diseases such as rheumatoid arthritis,
systemic lupus erythematosus and SSc itself [14–19].
Hence, the same cytokine, TGFβ, is strictly related to the
generation of functionally opposite T cell subpopulations,
effectors (Th17) and regulatory (Treg) ones, and the
functional fate of TGFβ-exposed T cells is mainly depen-
dent on the co-presence or not of pro-inflammatory
cytokines such as IL6 and IL1. In this context, the co-
existence in the same inflammatory milieu of TGFβ and IL6
in SSc lesions could favor the generation of effectors cells
at expenses of Treg, thus profoundly altering the homeo-
static equilibrium. This consideration prompted us to
perform a study aimed at evaluating phenotype and
function of both Th17 and Treg subsets in SSc patients.
Since several Treg subsets have been so far identified
belonging to both CD4+CD25+ and CD8+CD28− T cell
subpopulations, our analysis targeted both CD4+ and CD8+
Treg cell compartments. Collectively our study allowed the
achievement of a wide and comprehensive picture of T cell
immune responses in single SSc patients unveiling unprec-
edented findings related to the existence of an unbalanced
relationship between effector (mainly Th17-mediated) and
Treg activities.2. Patients and methods
2.1. Patients
Thirty-six patients, who attended the Division of Internal
Medicine and Clinical Immunology of the Department of
Internal Medicine, University of Genoa, were included in the
study after giving their informed consent. The study was
carried out in compliance with Helsinki Declaration and
approved by the Ethical Committee of San Martino Hospital in
Genoa. All the patients met the American College of
Rheumatology preliminary criteria for the classification of
SSc. Patients were subdivided as having limited cutaneous
SSc (lSSc, 24 patients) or diffuse cutaneous SSc (dSSc, 12
patients) on the basis of the extent of their skin involvement.
Active and stable diseases were identified taking into
account disease behavior according to Eustar disease score.
Clinical features of patients as well as treatments adminis-
tered are shown in Table 1.
Ten healthy subjects, matched for age and sex with SSc
patients, were studied as controls.2.2. Monoclonal antibodies (mAb)
For immunostaining and analysis by flow cytometer (FACS),
the following mAbs were used: allophycocianin (APC)-cyanin
7 conjugated anti-CD3, APC conjugated anti-CD25, CD8,
CD45R0, CD127, CD49d, phycoerythrin (PE) conjugated anti-
CD25, IL-4, CCR6, CCR7, Pe-cyanin 7 conjugated anti-IFN-γ,
CD8, CD25, fluorescein isothiocynate (FITC) conjugated anti-
IFN-γ, CD45RA (Becton Dickinson (BD) Biosciences); FITC,
Alexa-Fluor 647 conjugated anti-IL-17A (eBioscience); APC
conjugated anti-CD161 (Miltenyi Biotec); PerCP-cyanin 5
conjugated anti-CD8, CD4, CD28 (Biolegend); FITC conjugat-
ed anti-CD39 (Serotec) and PE conjugated anti-GITR (R&D
Systems). Fluorochrome-conjugated isotype matched Abs
were used as controls (BD Biosciences).2.3. Measurement of intracellular cytokines
Peripheral blood mononuclear cells (PBMC) were isolated
from heparinized venous blood by using density-gradient
centrifugation over Ficoll-Hypaque (Biochrom AG). The
intracellular expression of IFNγ, IL-4, IL-17A by PBMC was
analyzed as follows: the cells (resuspended in culture
medium conditioned with 10% autologous plasma at the
concentration of 1×107/ml) were stimulated with phorbol-
12-myristate-13-acetate (PMA 50 ng/ml, Sigma) and ionomi-
cine (2 μg/ml, Sigma) for 6 hours at 37 °C. Brefeldin (BFA
10 μg/ml, Sigma) was added to the cells for the last 4 hours
of incubation. After washings, the samples were stained with
fluorochrome-conjugated antibodies specific for surface
markers, before fixing and permeabilizing the lymphocytes
with the Cytofix/Cytoperm kit (BD Bioscience) following
manufacturer's instructions. The cells were washed in Perm-
Wash buffer (BD Bioscience) and incubated with the
fluorochrome-conjugated antibodies anti-IL4, IFN-γ, or IL-
17A. Thereafter the samples were washed in Perm-Wash
buffer, fixed with FACS-Lysing solution (BD Bioscience) and
stored at 4 °C. The cytokine profile was analyzed using a
FACSCanto flow cytometer (BD Bioscience) by a FACSDiva
software.2.4. Generation of antigen-specific T-cell lines
Antigen-specific CD4+ T-cell lines were generated by
stimulation of PBMC (6×106 cells), resuspended in culture
medium constituted by RPMI 1640 (Invitrogen) and 5%
autologous plasma, with autoclaved ifae and bodies from
Candida albicans (Ca). The cells were plated (2×106 cells/ml)
in a 24-well cluster plate (Costar, Cambridge, MA, USA) at
3×106 cells per well. Four days later IL-2 (Proleukin,
Eurocetus) was added to the wells at 30 U/ml final
concentration. After two weeks the cells were collected
and their cytokine profile was analyzed. To this end 3×105
cells/well were stimulated with PMA and ionomicyne in the
presence of BFA using the above described protocol. At this
stage the lines contained N95% CD4+ T-cells as assessed by
direct immunofluorescence. C. albicans organisms (ca-
organisms) were grown in RPMI 1640 medium for 2 days,
then washed twice in PBS, autoclaved and used at 2×106
bodies/ml final concentration in culture. This concentration,
Table 1 Clinical data of SSc patients enrolled in the study.
Patient no. Age Sex Type of disease Years from diagnosis Active disease Autoantibodies Treatment
1 73 f lSSc 5 no Anti-centromer Hydroxychloroquine
2 65 f lSSc 12 no Anti-centromer
3 64 f lSSc 20 no Anti-centromer Hydroxychloroquine,
bosentan
4 70 f lSSc 17 no Anti-centromer
5 64 f lSSc 10 no Anti-centromer
6 61 m lSSc 5 no Anti-centromer Cyclosporin A
7 73 f lSSc 15 no Anti-centromer
8 68 m lSSc 14 yes Anti-centromer
9 62 m lSSc 8 no Anti-centromer Hydroxychloroquine
10 75 f lSSc 7 yes Anti-centromer Bosentan
11 65 m lSSc 10 yes Anti-centromer Cyclosporin A
12 61 f dSSc 15 yes Anti-Scl70 Bosentan
13 57 f lSSc 23 yes Anti-centromer
14 77 f lSSc 12 yes Anti-centromer Hydroxychloroquine
15 65 f lSSc 9 yes Anti-centromer
16 78 f lSSc 29 yes Anti-centromer Bosentan
17 77 f lSSc 6 no Anti-centromer Hydroxychloroquine
18 50 f lSSc 15 no Anti-centromer
19 65 f lSSc 10 no Anti-centromer
20 62 f lSSc 5 no Anti-centromer Hydroxychloroquine
21 47 f dSSc 11 yes Anti-Scl70 Hydroxychloroquine
22 63 f lSSc 6 no Anti-centromer
23 79 m lSSc 2 no ANA speckled,
anti-Ro/La
24 57 f dSSc 10 no ANA speckled,
anti-Ro/La
25 68 m dSSc 14 yes ANA speckled,
anti-Ro/La
26 66 f dSSc 9 no ANA speckled
27 68 m dSSc 10 yes Anti-Scl70
28 60 f dSSc 3 yes Anti-Scl70 Cyclosporin A
29 64 f lSSc 9 no Anti-centromer
30 60 f dSSc 8 yes Anti-Scl70
31 61 f dSSc 10 yes Anti-centromer Hydroxychloroquine
32 60 f dSSc 2 yes Anti-Scl70 Hydroxychloroquine,
bosentan
33 58 f lSSc 12 yes Anti-centromer
34 76 f lSSc 12 yes Anti-centromer Bosentan
35 62 m dSSc 8 no Anti-Scl70 Bosentan
36 80 f dSSc 20 yes Anti-Scl70
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optimal for PBMC stimulation.
2.5. Purification of CD4+CD25+ Treg
CD4+CD25+ Treg were purified from PBMC of SSc patients and
healthy subjects by magnetic bead cell sorting using the
CD4+CD25+ regulatory T cell isolation kit, human (Miltenyi
Biotech). In brief the approach comprises a negative
selection of CD4+ T cells from PBMC by a cocktail of
biotinylated antibodies and anti-biotin microbeads for
depletion of non-CD4+ T cells, followed by subsequent
positive selection using CD25 microbeads. The suppressivecapability of CD4+CD25+ Treg and the phenotype were
evaluated ex-vivo.
2.6. In vitro generation of CD8+CD28− Treg from
the peripheral blood of healthy subjects
CD8+CD28− T cells were isolated from PBMC by repeated run
of magnetic bead cell sorting using microbeads conjugated
with mAb specific for the CD8 and the CD28 antigens
(Dynabeads, Invitrogen).
Purified CD8+CD28− T lymphocytes (1×105 cells/well),
resuspended in culture medium constituted by RPMI 1640
culture medium (Invitrogen) added with 10% fetal calf serum
252 D. Fenoglio et al.(Invitrogen), 2% glutamine (Invitrogen), were incubated with
20 U/ml of IL-2 (Proleukin, Eurocetus) and 40 ng/ml of IL-10
(R&D System) in 96 well flat bottomed plates (Sardsted) at
37 °C for 7 days.
The regulatory activity and the membrane antigen study
were performed on both freshly ex-vivo purified CD8+CD28−
T cells and on in vitro generated CD8+CD28− Treg.2.7. Proliferation suppression assay
The suppressive activity of Treg was evaluated by monitoring
the inhibition of dye dilution in PBMC stained with CFDA-SE
(5 μM) (Molecular Probes, Invitrogen) before the test.
Thereafter, the cells were pulsed with the anti-CD3 UCTH-
1 mAb (5 μg/ml, BD Bioscience) and cultured for 5 days in a
96 well flat bottomed plate (1×105 cells/well) in the
presence (or not) of CD8+CD28− or CD4+CD25+ T lympho-
cytes (1×105 cells/well). Then the sample were washed in
PBS and acquired by flow cytometer. The dead cells were
excluded from analysis by adding 7AAD (BD Bioscience)
before acquisition.Figure 1 Analysis of frequencies of CD4+IFNγ+ (panel A), CD4+CCR
in the circulation of SSc patients and healthy controls. Panel D: flo
representative patients no. 8.2.8. Statistical analyses
Statistically significant differences between mean percent
concentrations of different T cell subsets, as well as between
mean percent suppressor activities of Treg cells from SSc
patients and controls were analyzed by Mann–Whitney test for
nonparametric values. Statistically significant correlation be-
tween variables was searched by Spearman test for nonpara-
metric data. Contingency analysis on frequency of SSc patients
and controls showing ex vivo freshly isolated CD8+ Treg was
performed using Fisher's exact test. Calculations were per-
formed using the GraphPad Prism, Version 4.00 software.
3. Results
3.1. Increased Th17 cell concentration in the
peripheral blood of SSc patients
In order to achieve comprehensive information on the
composition of the effector T cell compartment in SSc
patients, circulating CD4+ T cells were analyzed for their6+IL17+ (panel B) and CD4+CCR6+ (panel C) T cell subpopulations
w cytometry analysis of CD4+CCR6+IL17+ T cells in PBMC from
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characterizing Th1, Th2 and Th17 T cell subsets, respective-
ly. Decreased concentration of CD4+IFNγ+ T cells was
observed in SSc patients with respect to healthy controls,
independently from type (diffuse or limited) and stage
(activated or stable) of disease (Fig. 1A). No differences of
CD4+IL4+ T cell concentration was detected between
patients and controls (not shown). Since Th17 have been
reported to be phenotypically characterized by the expres-
sion of the CCR6 chemokine receptor [20], the frequency of
CD4+CCR6+IL17+ T cells among total CD4+ T cells was
analyzed. Although no significant differences in the frequen-
cy of CD4+CCR6+ T cells were present between SSc patients
and controls (Fig. 1C), the analysis of CD4+CCR6+IL17+ T cells
demonstrated a statistically significant increase of their
frequency in SSc patients with respect to controls indepen-
dently from type or stage of disease (Fig. 1B). Fig. 1D shows
the results of the representative analysis performed on PBMC
from patient no. 8.
3.2. The immune response in SSc patients is skewed
toward Th17 cell generation/expansion
In order to dynamically analyze the immune response of SSc
patients, PBMC were stimulated using a combination of anti-
CD3 and anti-CD28 specific mAbs, and subsequently the
frequencies of CD4+IFNγ+, CD4+IL4+, and CD4+CCR6+IL17+
cell subpopulations were analyzed. Upon these experimental
conditions, the frequency of CD4+IFNγ+ T cells was lower in
SSc patients than in controls (Fig. 2A), the frequency of CD4
+CCR6+IL17+ cells was significantly higher in SSc patients
with respect to healthy subjects (in particular, in patientsFigure 2 Analysis of frequencies of CD4+IFNγ+ (panel A) and
CD4+CCR6+IL17+ (panel B) T cell subpopulations in PBMC from
SSc patients and controls stimulated by an anti-CD3 mAb and an
anti-CD28 mAb.with active disease) (Fig. 2B), and no detectable IL4-
secreting T cells were generated (not shown).
To verify the consistency of these findings in an antigen-
dependent setting, a new array of experiments was
performed in which PBMC were stimulated with ifae and
bodies of C. albicans (Ca). This choice originates from the
knowledge that protection against Ca infection is mainly
Th17-related [21] and that Ca preferentially induces IL17
secretion through the interaction between the Ca mannans
and the macrophage mannose receptor [22]. Upon Ca
stimulation, unchanged or reduced (in patients with active
disease) frequency of CD4+IFNγ+ T cells was detected
(Fig. 3A), while higher frequency of CD4+CCR6+IL17+ T
cells, independently from type or stage of disease, was
observed in SSc patients with respect to healthy controls
(Fig. 3B).3.3. CD4+CD25+ Treg in SSc patients
The finding of a spontaneously skewed T cell response
toward the pro-inflammatory Th17 cell type might suggest
that the healthy balance between effector and regulatory
immunity is broken and that a decrease of Treg functions
could parallel the effector immune responses in SSc, leading
to immune-mediated lesions. With this in mind, phenotypic
and functional features of CD4+CD25+highCD127low Treg were
examined. Reduced frequency of these cells was observed in
the circulation of SSc patients with respect to controls
(Fig. 4A and E). When the function of CD4+CD25+highCD127low
Treg was analyzed, decreased levels of suppressive activity
were observed in patients with diffuse and active disease
with respect to healthy controls (Fig. 4B). Hence, in SScFigure 3 Analysis of frequencies of CD4+IFNγ+ (panel A) and
CD4+CCR6+IL17+ (panel B) T cell subpopulations in PBMC from
SSc patients and controls stimulated by bodies of Ca.
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merical and/or functional defects.3.4. CD8+CD28− Treg in SSc patients
At variance with CD4+CD25+ Treg cells, no specific markers
for CD8+ Treg subsets have been so far identified: hence, a
precise phenotypic enumeration of these cells is not feasible
at the moment. However, since we had previously shown
that these cells (and their precursors as well) do not express
the CD28 molecule at their cell surface [23], the frequency of
CD8+CD28− T cells was analyzed in both SSc patients andFigure 4 Analysis of frequency and function of Treg subpopulation
circulating CD4+CD25+highCD127− Treg cells; panel B: suppressive ac
circulating CD8+CD28− T cells; panel D: suppressor activity exerted b
of CD4+CCR6+IL17+ and CD8+CD28− T cells in PBMC from representahealthy subjects. SSc patients showed increased levels of
circulating CD8+CD28− T cells independently from the type
(limited or diffuse) of disease (Fig. 4C). In order to
functionally analyze CD8+ Treg, the suppressive function
was tested on both ex vivo freshly isolated CD8+CD28− T cells
and in vitro generated CD8+ Treg. Concerning ex vivo freshly
isolated CD8+CD28− T cells, in our experimental setting cells
derived from healthy subjects never showed an efficient
suppressive activity (≥ 25%). In contrast, 11 out of 21 (52%) of
tested SSc patients (9 affected with diffuse and 12 with
limited disease, 8 with active and 13 with stable disease)
presented a suppressor activity≥25% exerted by ex vivo
freshly isolated CD8+CD28− T cells (P=0.005). When thes from SSc patients and healthy controls. Panel A: frequency of
tivity of CD4+CD25+highCD127− Treg cells; panel C: frequency of
y in vitro generated CD8+ Treg; panel E: flow cytometry analysis
tive patients no. 8. *Pb0.01 vs controls; **Pb0.05 vs controls.
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analyzed, significantly reduced values were detected in
patients affected with diffuse or active disease (Fig. 4D).3.5. Co-existence of alterations concerning both
Th17 and Treg compartments in single patients
The results so far exposedhighlight the skewing towardTh17cell
function and the presence of Treg alterations as immunological
stigmata of SSc patients. In order to verify whether the two
phenomena tend to associate in single patients, a correlation
analysis was performed. The presence of increased concentra-
tion of circulating Th17 cells, with respect to the range of
concentrations detected in our series of control subjects
(0.1–0.3%), was considered as the variable related to the Th17
cell compartment. The existence of any alteration of the Treg
compartment, taking into to consideration (a) lowered concen-
tration of circulating CD4+CD25+CD127− Treg with respect to
the normal range detected in our series of control subjects
(2–3.5%), (b) functional deficiency of CD4+CD25+CD127− Treg
and (c) functional deficiency of CD8+ Treg, was considered as
the variable related to the Treg compartment. Table 2 shows
that a statistically significant correlation (P=0.02)was detected
between the two variables, likely suggesting the preferential
association of increased Th17 immune responses with altered
Treg functions in single SSc patients.4. Discussion
The results of our studies show that: a) CD4+CCR6+ Th17 cells
are increased in the circulation of SSc patients; b) T cell
immune response in SSc patients is polarized toward the
Th17 cell compartment; c) numerical and functional altera-
tions of Treg, affecting both CD4+CD25+ and CD8+ Treg
subpopulations, are consistently detected in SSc patients; d)
alterations of CD4+CCR6+ Th17 and of Treg co-exist and
correlate in single SSc patients.
The discovery in the 1980s/1990s of the Th1/Th2
dichotomy [24,25] led to the classification of immune-
mediated diseases into predominantly Th1 or Th2 polarized
diseases [26]. SSc was then classified as Th2-linked disease
on the basis of the predominance of Th2 cells in patient skin
and of the increased serum concentration of Th2-related
markers (such as CD30 and IL4) [26–28].Table 2 Correlation between the percentage of Th17 cells in th
compartment in single patients.
Patient no.
1 2 3 4 5 6 7 8 9 10 11 12 1
Th17* 1 1 1 0 0 0 0 0 0 1 1 1 1
Treg* 1 1 1 0 1 0 1 1 1 1 1 1 1
Th17: 0 was attributed to SSc patients showing Th17 percentage concen
0.3%) and 1 was attributed to patients with increased values.
Treg: 0 was attributed to SSc patients without alterations of Treg (conside
Treg and function of CD4+ or CD8+ Treg) and 1 was attributed to patient
*A statistically significant correlation was detected between the two vThe recent unveiling of a new effector T cell subset
mainly characterized by its secretion of IL17 (Th17) opened
the way for the achievement of new pathogenic insights
regarding chronic inflammatory diseases and autoimmune
diseases in particular [29–32]. Indeed, several autoimmune
diseases have been already found associated with abnormal
Th17-driven immune responses [33–36]. In particular, Th17
have been linked to psoriasis, rheumatoid arthritis, Crohn
disease. The importance of IL-17 in SSc is known from a long
time [9], and more recently the importance of a possible
Th17 mediated mechanism(s) in the development of this
disease is under debate [10,11,37,38].
Analysis of Th17 cells in the circulation it is not an easy
task, due to the very low number of these cells in periphery
that makes them hardly detectable. However, the finding
that Th17 cells are mainly characterized by the expression of
the CCR6 chemokine receptor [39] provides a useful tool for
restricting and targeting the search of IL17-secreting cells
within a more defined subpopulation.
Here, the analysis of CD4+CCR6+IL17+ T cells in SSc
patients allowed us to show for the first time that Th17 cells
are increased in the peripheral blood of SSc patients in
comparison to healthy subjects.
Moreover, we also observed that stimulation of T cells
from SSc individuals with anti-CD3 plus anti-CD28 mAbs
expanded preferentially Th17 cells. Similar results were
observed when T cells from SSc patients were activated by a
complex antigen known to expand IL-17 producing cells (such
as C. albicans) [21]. Indeed, in both cases, we found that SSc
patients expanded Th17 cells at a significantly higher
frequency in comparison to healthy control subjects.
Taken together, these two findings strongly suggest that
Th17 cells play a pivotal role in SSc. On the other hand, it is
well known that SSc is characterized by elevated production
of TGFβ, IL6 and IL1 that are all biological agents strictly
related to Th17 differentiation and/or expansion) [2–8],
thus further supporting the hypothesis that this disease may
be strongly related to a polarization of the immune response
toward the Th17 pathway. This is even more intriguing in
light of the recent findings showing that human fibroblasts
may per sè promote Th17 response [40], thus unveiling a
possible role of fibroblasts in determining the kind of T cell
polarization in SSc.
Th17 is an effector T cell: one leading hypothesis on the
pathogenesis of autoimmune diseases proposes the develop-
ment of an unbalanced relationship between effector ande peripheral blood and the presence of alterations in the Treg
3 14 15 16 17 18 19 20 21 22 23 24
1 0 1 0 1 1 1 0 0 1 1
1 1 1 1 1 1 1 0 1 1 1
trations comprised in the range detected in healthy controls (0.1–
ring both percentage concentration in the circulation of CD4+CD25+
s with any type of Treg alteration.
ariables (P=0.02, r=0.44).
256 D. Fenoglio et al.regulatory arms of the immune system as a relevant event
[12,13].
An unbalanced ratio between effector and regulatory T
cell responses as pathogenic mechanism leading to the onset
of autoimmune phenomena would imply that abnormal
activation of effector cells may associate with deficiencies
in the regulatory compartment.
Accordingly with this hypothesis, a complex of alterations
was found in our series of SSc patients affecting frequency
and function of both CD4+CD25+ and CD8+ Treg subsets. In
particular, reduced frequency and impaired function of
CD4+CD25+ Treg were observed in our series of SSc patients.
This is partially in contrast with what was reported by
Radstake et al. [41] who found increased frequency of
CD4+CD25+ Treg in their SSc patients. Although it is difficult
to identify a clear explanation for such discrepancy, one
possibility could be the occurrence of periodical variations of
Treg frequency in the circulation of SSc patients in response
to unknown factors. Accordingly, ex vivo analyses of freshly
isolated cells showed the presence of effective CD8+ Treg in
the circulation of 52% of SSc patients, but not in that of
healthy controls, an observation suggesting relevant recir-
culation phenomena involving specifically this Treg subset in
SSc patients. Future studies aimed at describing in detail the
kinetics of Treg subpopulations in the blood of SSc patients
could help solve this issue.
Altogether these findings, underlining the co-existence of
divergent and pleiotropic alterations concerning both effec-
tor and regulatory immune responses, support the concept
that SSc could, at least in part, originate from an altered
relationship and an uncorrect interplay between functionally
different T cell compartments more than from structural/
molecular deficiencies targeting one specific T cell subset.
To this regard, it is of particular interest to note that Th17
and Treg seem to be closely linked and their origin regulated
by co-evolutionary processes [reviewed in 42]. It is well
known that SSc fibroblasts are able to produce several
cytokines critical to regulate T cell polarization and
function, as we already mentioned. On this basis, we may
hypothesize that the over production of given cytokines, as
for instance TGF-beta, from SSc fibroblast could promote
Th17 response while inhibiting Treg differentiation, thus
leading to a chronic inflammation.
In conclusion here we show for the first time that SSc
patients display a T cell response characterized by expansion
of Th17 cells and a preferential polarization toward Th17
upon specific and non specific stimulation. This feature is
counterbalanced by a diminished capacity to develop T cell
regulation and it may be worth to explore the possibility that
these phenomena are, to some extent, regulated by the
cytokine milieu characterizing SSc. These results could
therefore bring new lines of investigations on the role of T
cell response in SSc and, in case, lead to new therapeutical
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